Renaissance Technologies LLC Acquires New Shares in Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Renaissance Technologies LLC purchased a new stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 19,200 shares of the company’s stock, valued at approximately $142,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sanders Morris Harris LLC acquired a new stake in shares of Actinium Pharmaceuticals during the 1st quarter valued at $78,000. Vanguard Group Inc. grew its holdings in shares of Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the last quarter. Virtu Financial LLC increased its stake in shares of Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after buying an additional 62,459 shares during the period. Bank of New York Mellon Corp raised its holdings in Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Actinium Pharmaceuticals by 23.4% during the 2nd quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock worth $293,000 after buying an additional 7,525 shares during the period. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Stock Up 10.4 %

Shares of ATNM opened at $1.80 on Monday. The firm’s fifty day moving average price is $1.92. Actinium Pharmaceuticals, Inc. has a 12 month low of $1.33 and a 12 month high of $10.24. The company has a market capitalization of $53.60 million, a PE ratio of -1.19 and a beta of 0.14.

Actinium Pharmaceuticals (NYSE:ATNM) last released its earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.02. As a group, research analysts forecast that Actinium Pharmaceuticals, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ATNM. StockNews.com upgraded shares of Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 8th. HC Wainwright lowered their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. B. Riley downgraded Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $16.00 to $2.00 in a report on Wednesday, August 7th. Finally, Maxim Group decreased their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Actinium Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $11.40.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).